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Recombinant protein biopharmaceuticals are the top selling class of drugs, with global annual sales exceeding 
100 billion USD. The majority of biopharmaceuticals are currently made in Chinese hamster ovary (CHO) cells, a 
transformed cell type originally isolated in the 1950s. The adaptability and utility of CHO cell factories derives 
from our exploitation of their acquired genetic/functional variation using high-throughput functional screening 
and selection processes which enable industry to isolate and maintain cell factories with unusual and desirable 
properties.  However, we still have a limited understanding of enabling cellular mechanisms that underpin the 
ideal manufacturing phenotype.  This knowledge would permit design and construction of intrinsically better 
cell factories using the new concepts and tools of systems and synthetic biology.  We now have the potential to 
provide disruptive new solutions for cell and process engineering, where we will be able to create bespoke cell 
factories with a predictable ability to manufacture a new generation of more complex biopharmaceutical 
proteins. 
  
 
